Treats non-cystic fibrosis bronchiectasis (NCFB). Sold as Brinsupri. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Brensocatib (sold as Brinsupri), first approved Aug 12, 2025, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Brinsupri | Part D | $145M | New | 8,267 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK) of Midazolam in Healthy ParticipantsHealthy Volunteers · Insmed Incorporated | Phase 1 | Not yet recruiting | Oct 5, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Aug 12, 2025 | BrinsupriNDA 217673 · New molecular entity | Insmed Inc | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
